Generic selexipag could offer cheaper option for rare lung disease
NCT ID NCT07694128
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests whether a new generic tablet containing selexipag works the same as the brand-name drug Uptravi. Healthy adults aged 18 to 55 take a single dose of each version under fed conditions, and researchers compare how much drug gets into the bloodstream. The goal is to see if the generic can be used as a lower-cost alternative for treating pulmonary arterial hypertension.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selexipag
- What this could lead to
- If successful, this could provide a more affordable generic version of Uptravi for people with pulmonary arterial hypertension.
- What could go wrong
- This is an early-phase bioequivalence study in healthy volunteers, not patients. It only measures drug levels in the blood, not actual treatment effects or safety in the target population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Veeda Clinical Research Ltd.
Ahmedabad, Gujarat, 380 015, India